Alec Saitman (Presenter)
Providence Regional Laboratories
Bio: Dr. Saitman received his Ph.D. in Organic Chemistry at the University of California, San Diego where he focused his research on the total synthesis of marine natural products. He completed his fellowship training in Clinical Chemistry and Toxicology in the Department of Pathology at the University of California, San Diego under the guidance of Dr. Robert Fitzgerald. Dr. Saitman is double boarded by the American Board of Clinical Chemistry in clinical chemistry and clinical toxicology. He is currently the director of clinical toxicology and special chemistry at Providence Regional Laboratories in Portland Oregon.
Authorship: Alec Saitman
Providence Regional Laboratories, Portland Oregon
| Short Abstract This session talk provides case studies which highlight the superiority of mass spectrometry when compared to other methodologies. Each case study describes how an added piece of mass spectrometry data can alter the entire clinical interpretation of a patient sample. |
Long Abstract
Introduction
This session talk provides case studies which highlight the superiority of mass spectrometry when compared to other methodologies. Each case study describes how an added piece of mass spectrometry data can alter the entire clinical interpretation of a patient sample.
Methods
The case examples to be discussed were identified in a routine clinical laboratory setting. The process of identifying these examples is built into our data review procedure. We will discuss common scenarios that may be encountered in any laboratory performing drug confirmation testing using mass spectrometry based methods.
Results
Specific case studies will describe:
1. How a negative or positive confirmation of an illicit drug of abuse impacts patient care.
2. Why ion ratios are so important in the correct identification of any compound.
3. Identification of non-prescribed drugs in patient samples using mass spectrometry methods.
4. Use of metabolites and/or metabolite patterns to identify those patients compliant with their medication regimens and those who are not.
Conclusions & Discussion
At the end of this session, participants will be able to:
1. Recognize how mass spectrometry qualifier ions are used to confirm drug positive results.
2. Identify atypical mass spectrometry results given a patient’s clinical history and prescription patterns.
3. Differentiate between patient compliance and patient non-compliance using mass spectrometry.
References & Acknowledgements:
N/A
| Description | Y/N | Source |
| Grants | no | |
| Salary | no | |
| Board Member | no | |
| Stock | no | |
| Expenses | no |
IP Royalty: no
| Planning to mention or discuss specific products or technology of the company(ies) listed above: | no |